Screening of frequent variants associated with congenital hypothyroidism: a comparison with next generation sequencing.
Congenital hypothyroidism
Gene screening
Next generation sequencing
Sanger sequencing
Journal
Endocrine journal
ISSN: 1348-4540
Titre abrégé: Endocr J
Pays: Japan
ID NLM: 9313485
Informations de publication
Date de publication:
28 Dec 2021
28 Dec 2021
Historique:
pubmed:
9
7
2021
medline:
5
4
2022
entrez:
8
7
2021
Statut:
ppublish
Résumé
Congenital hypothyroidism (CH) is considered the most common congenital endocrine disorder of genetic origin. Next generation sequencing (NGS) is the standard method for identifying genetic mutations, but it is an expensive and complex technique. Therefore, we propose to use Sanger sequencing to identify selected variants of the four most common CH-causative genes: DUOX2, TG, TSHR, and PAX8. To analyze the performance of Sanger sequencing, we compared its variant detection ability with that of a CH NGS panel containing 53 genes. We performed Sanger sequencing of selected variants and panel NGS analysis of 25 Japanese patients with CH. Sanger sequencing identified nine variants in seven patients, while NGS identified 24 variants in 14 patients. Of these, eight, five, eight, two, and one were found to be potentially pathogenic in DUOX2, TSHR, TG, UBR1, and TPO genes, respectively. The percentage of detectable variants using Sanger sequencing compared with NGS was 37.5% (9/24 variants), whereas the percentage of detectable cases carrying variants using Sanger sequencing compared with NGS was 50% (7/14 patients). We proposed a system for screening commonly identified CH-related variants by Sanger sequencing. Sanger sequencing could therefore identify about a third of CH-causative variants, so is considered an effective and efficient form of pre-screening before NGS.
Identifiants
pubmed: 34234053
doi: 10.1507/endocrj.EJ21-0353
doi:
Substances chimiques
Dual Oxidases
EC 1.11.1.-
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM